- Home
- TRVI vs VYGR Comparison
TRVI vs VYGR Comparison
Compare TRVI & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRVI
- VYGR
- Stock Information
- Founded
- TRVI 2011
- VYGR 2013
- Country
- TRVI United States
- VYGR United States
- Employees
- TRVI N/A
- VYGR N/A
- Industry
- TRVI Biotechnology: Pharmaceutical Preparations
- VYGR Biotechnology: Pharmaceutical Preparations
- Sector
- TRVI Health Care
- VYGR Health Care
- Exchange
- TRVI Nasdaq
- VYGR Nasdaq
- Market Cap
- TRVI 341.4M
- VYGR 342.5M
- IPO Year
- TRVI 2019
- VYGR 2015
- Fundamental
- Price
- TRVI $3.76
- VYGR $5.07
- Analyst Decision
- TRVI Strong Buy
- VYGR Strong Buy
- Analyst Count
- TRVI 8
- VYGR 9
- Target Price
- TRVI $9.31
- VYGR $15.53
- AVG Volume (30 Days)
- TRVI 659.4K
- VYGR 385.3K
- Earning Date
- TRVI 11-06-2024
- VYGR 02-26-2025
- Dividend Yield
- TRVI N/A
- VYGR N/A
- EPS Growth
- TRVI N/A
- VYGR N/A
- EPS
- TRVI N/A
- VYGR 0.47
- Revenue
- TRVI N/A
- VYGR $163,784,000.00
- Revenue This Year
- TRVI N/A
- VYGR N/A
- Revenue Next Year
- TRVI N/A
- VYGR N/A
- P/E Ratio
- TRVI N/A
- VYGR $10.87
- Revenue Growth
- TRVI N/A
- VYGR 3.40
- 52 Week Low
- TRVI $1.27
- VYGR $4.99
- 52 Week High
- TRVI $4.68
- VYGR $10.66
- Technical
- Relative Strength Index (RSI)
- TRVI 48.03
- VYGR 34.22
- Support Level
- TRVI $3.63
- VYGR $4.99
- Resistance Level
- TRVI $4.06
- VYGR $5.45
- Average True Range (ATR)
- TRVI 0.30
- VYGR 0.26
- MACD
- TRVI -0.09
- VYGR -0.07
- Stochastic Oscillator
- TRVI 12.21
- VYGR 6.25
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.